Please login to the form below

Not currently logged in
Email:
Password:

PD-1 inhibitor

This page shows the latest PD-1 inhibitor news and features for those working in and with pharma, biotech and healthcare.

Breath test could predict response to immunotherapy

Breath test could predict response to immunotherapy

Although checkpoint inhibitors, including PD-1/PD-L1 blockbusters Keytruda (pembrolizumab) from MSD and Opdivo (nivolumab) from Bristol-Myers Squibb, have improved survival in various cancer areas, most patients do not ... PD-1 and PD-L1 inhibitors block

Latest news

  • 'Therapeutic overcrowding' could hit big pharma returns 'Therapeutic overcrowding' could hit big pharma returns

    Exhibit A in their analysis is the six PD-1/PD-L1 checkpoint inhibitor drugs already on the market, with new entrants still to come from Asian companies, that are predicted ... Jefferies says newer classes of biologics could add at least $30bn in

  • BeiGene gets speedy US review for lymphoma drug zanubrutinib BeiGene gets speedy US review for lymphoma drug zanubrutinib

    The MCL filing is based on data from a phase 1/2 trial of BeiGene’s BTK inhibitor in patients with B-cell lymphomas, as well as an aggregate of 123 ... In addition to zanubrutinib, BeiGene is also developing PD-1 inhibitor tislelizumab – which has

  • AZ’s Imfinzi combo bombs again in non-small cell lung cancer AZ’s Imfinzi combo bombs again in non-small cell lung cancer

    The NEPTUNE study compared PD-L1 inhibitor Imfinzi (durvalumab) and AZs experimental CTLA4 inhibitor tremelimumab to standard platinum-based chemotherapy in previously-untreated patients with advanced NSCLC. ... The readout will also be a concern to

  • Positive first-line phase 3 results for Tecentriq Positive first-line phase 3 results for Tecentriq

    Tecentriq was the third drug to hit the growing PD-1/PD-L1 inhibitor category, with Bristol-Myers Squibb’s Opdivio and Merck &Co’s Keytruda the first to establish a ... Roche's PD-L1 inhibitor was the  first to get approval for an immuno-oncology

  • Celgene cuts back Jounce alliance ahead of BMS merger Celgene cuts back Jounce alliance ahead of BMS merger

    Jounce now takes back full worldwide rights to the rest of its pipeline, including the ICOS-targeting vopratelimab, PD-1 inhibitor JTZ-4014 and all discovery programmes. ... BMS has its own anti-ICOS agonist, BMS-986226, in clinical trials and the

More from news
Approximately 3 fully matching, plus 214 partially matching documents found.

Latest Intelligence

  • Immuno-oncology in 2019: the rapid evolution continues Immuno-oncology in 2019: the rapid evolution continues

    cells to identify and fight cancer: the PD-1 and PD-L1 checkpoint inhibitor immunotherapies. ... PD-1/PD-L1 inhibitors: Keytruda is King, but the market is developing fast.

  • Drug launches to watch in 2019 Drug launches to watch in 2019

    1 inhibitor Keytruda (pembrolizumab) was backed for cancers harbouring a biomarker known as microsatellite instability-high (MSI-H). ... t the only oral JAK inhibitor developer with its eye on that particular prize.

  • Is China ready for a pharmaceutical gold rush?

    The programmed cell death 1 (PD-1) immune checkpoint inhibitor works by restoring the immune system’s ability to fight cancer tumours. ... Competition time. At the same time, Merck’s PD-1 agent, Keytruda, is hot on Opdivo’s heels.

  • Deal Watch January 2017 Deal Watch January 2017

    3, 050. Pieris Pharmaceuti-cals. Servier. Exclusive licence outside USA. PRS 332 PD-1-targeting bispecific checkpoint inhibitor and 4 other candidates. ... 775. BMS | Ono. Merck. Patent settlement. PD-1 antibody Keytruda - (pembrolizumab).

  • Pharma deals in September 2015 Pharma deals in September 2015

    taking rights (outside China) to a PD-1 inhibitor (POC ready) from Jaingsu Hengrui Medicine (SHR-1210) for advanced solid tumours paying a modest $25m upfront but up to $770m in ... Acquisition - company. 1, 230. Jiangsu Hengrui Medicine. Incyte.

More from intelligence
Approximately 0 fully matching, plus 7 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Six Degrees Medical Consulting

For over a decade, our medical communication services have helped pharmaceutical companies optimize their brand, disease and corporate objectives. Building...

Latest intelligence

Report: Customer experience, shaping digital healthcare
In this issue of ‘Perspective’ we speak with industry experts to learn about the world of digital healthcare, and how pharma is beginning to utilise these modern technologies to enhance...
Biomarker
Encouraging signs in biomarker R&D
The cancer immunotherapy firms ramping-up biomarker R&D...
Programmatic methodology and why you should be using it
What is it? How does it work? Why is everyone talking about it? By Richard Webb - Associate Director...

Infographics